Company InventisBio Co., Limited

Equities

688382

CNE100005Q22

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Ratings for InventisBio Co., Limited

EPS Revisions

Annual profits - Rate of surprise

Sector Bio Therapeutic Drugs

End-of-day quote Shanghai S.E. Other stock markets 03:30:00 31/05/2024 am IST			5-day change	1st Jan Change
8.71 ^CNY	+0.46%		+2.11%	-42.47%

29/04	InventisBio Co., Limited Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
11/04	Sino Biopharmaceutical Presents Cancer Drug's Phase-II Clinical Trial Results at AACR 2024	MT

InventisBio Co Ltd is a China-based company mainly engaged in the research and development of innovative drugs. The Company's main product is still in clinical development. The Company's core products mainly focus on major disease areas such as oncology and metabolic diseases. The Company's products include D-0120, D-0502, D-1553, BPI-D0316 and others.

Number of employees: 221

CNY in Million	2022	Weight	2023	Weight	Delta
Innovative Drugs 100.0 %	0	nan %	186	100.0 %	-

CNY in Million	2022	Weight	2023	Weight	Delta
China 100.0 %	0	nan %	186	100.0 %	-

Managers	Title	Age	Since
Yao Lin Wang CEO	Chief Executive Officer	61	11/13/11
Lu Wei Shi DFI	Director of Finance/CFO	39	01/15/01
Ling Zhang CTO	Chief Tech/Sci/R&D Officer	60	01/18/01
Ji fang Weng CTO	Chief Tech/Sci/R&D Officer	43	01/19/01
Dan Dan Ren BRD	Director/Board Member	38	28/20/28
Xing Dai BRD	Director/Board Member	49	01/15/01
Yue Heng Jiang BRD	Director/Board Member	53	01/18/01

Members of the board	Title	Age	Since
Yao Lin Wang CEO	Chief Executive Officer	61	11/13/11
Yi Fu Liu BRD	Director/Board Member	45	30/23/30
Xin Miao Dai BRD	Director/Board Member	61	09/20/09
Yue Heng Jiang BRD	Director/Board Member	53	01/18/01
Xing Dai BRD	Director/Board Member	49	01/15/01
Lu Wei Shi DFI	Director of Finance/CFO	39	01/15/01
Wen Chen BRD	Director/Board Member	56	09/20/09
Jia Yan BRD	Director/Board Member	53	09/20/09
Dan Dan Ren BRD	Director/Board Member	38	28/20/28
Ji fang Weng CTO	Chief Tech/Sci/R&D Officer	43	01/19/01

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	576,658,841	286,846,537 ( 49.74 %)	0	49.74 %

Name	Equities	%	Valuation
Hillhouse Investment Management Ltd. (Invest) 7.245 %	28,749,939	7.245 %	39 M ¥
GF Fund Management Co., Ltd. 3.344 %	13,268,584	3.344 %	18 M ¥
ICBC Credit Suisse Asset Management Co., Ltd. 2.886 %	11,452,849	2.886 %	15 M ¥
Bank of China Investment Management Co., Ltd. 2.324 %	9,220,975	2.324 %	12 M ¥
Penghua Fund Management Co., Ltd. 2.039 %	8,093,052	2.039 %	11 M ¥
First Seafront Fund Management Co., Ltd. 1.993 %	7,906,933	1.993 %	11 M ¥
Zhonghai Fund Management Co., Ltd. 1.411 %	5,597,683	1.411 %	8 M ¥
Maxwealth Fund Management Co., Ltd. 1.175 %	4,664,058	1.175 %	6 M ¥
Hwabao WP Fund Management Co., Ltd. 1.110 %	4,403,832	1.110 %	6 M ¥
HSBC Jintrust Fund Management Co. Ltd. 0.8754 %	3,473,684	0.8754 %	5 M ¥

Name	Equities	%	Valuation
LAV Management Co., Ltd. 10.12 %	47,558,248	10.12 %	64 M ¥
OrbiMed Advisors Private Equity 6.118 %	28,749,900	6.118 %	39 M ¥

InventisBio, Co., Ltd.

Room 210, 4, Lane 67 Libing Road

201203, Shanghai

http://www.inventisbio.com

address InventisBio Co., Limited(688382)

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

8.71 CNY

Average target price

18.5 CNY

Spread / Average Target

+112.40%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
INVENTISBIO CO., LIMITED	-42.47%	69Cr
VERTEX PHARMACEUTICALS INCORPORATED	+11.91%	12TCr
REGENERON PHARMACEUTICALS, INC.	+11.60%	11TCr
BIONTECH SE	-4.68%	2.43TCr
ARGENX SE	-0.82%	2.2TCr
GENMAB A/S	-10.12%	1.82TCr
WUXI APPTEC CO., LTD.	-42.12%	1.64TCr
BEIGENE, LTD.	-17.47%	1.56TCr
NEUROCRINE BIOSCIENCES, INC.	+2.77%	1.36TCr
SAREPTA THERAPEUTICS, INC.	+34.58%	1.23TCr

Bio Therapeutic Drugs